Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease
J Schultheiss, Remi Mahmoud, J Louwers, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 54, Iss. 10, pp. 1298-1308
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study
Anthony Buisson, Maria Nachury, Maud Reymond, et al.
Clinical Gastroenterology and Hepatology (2022) Vol. 21, Iss. 9, pp. 2338-2346.e3
Open Access | Times Cited: 50
Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn’s Disease: A Pragmatic Randomized Trial
Michael D. Kappelman, David A. Wohl, Hans Herfarth, et al.
Gastroenterology (2023) Vol. 165, Iss. 1, pp. 149-161.e7
Open Access | Times Cited: 25
Pathogenesis and precision medicine for predicting response in inflammatory bowel disease: advances and future directions
Robert D. Little, Thisun Jayawardana, S Koentgen, et al.
eGastroenterology (2024) Vol. 2, Iss. 1, pp. e100006-e100006
Open Access | Times Cited: 8
Discontinuation of Infliximab Therapy in Patients with Crohn’s Disease
Sine Buhl, Casper Steenholdt, Jørn Brynskov, et al.
NEJM Evidence (2022) Vol. 1, Iss. 8
Closed Access | Times Cited: 34
Intestinal tissue levels of anti-TNF alpha, antibodies, and cytokines in paediatric Crohn disease
Vojtěch Dotlačil, Štěpán Coufal, Tereza Lerchová, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Introduction
Keisuke Aoki
Springer theses (2025), pp. 1-9
Closed Access
Therapeutic drug monitoring and immunogenetic factors associated with the use of adalimumab in Crohn’s disease patients
Lívia Moreira Genaro, Juliana Carron, Marina Moreira de Castro, et al.
International Journal of Immunopathology and Pharmacology (2025) Vol. 39
Open Access
Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease
Remi Mahmoud, H. Schultheiss, J Louwers, et al.
Clinical Gastroenterology and Hepatology (2022) Vol. 20, Iss. 11, pp. 2577-2587.e6
Open Access | Times Cited: 23
Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease—Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics
Robert D. Little, Mark G. Ward, Emily K. Wright, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 20, pp. 6173-6173
Open Access | Times Cited: 23
Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis
Edo Savelkoul, Pepijn W. A. Thomas, Lauranne Derikx, et al.
Inflammatory Bowel Diseases (2022) Vol. 29, Iss. 10, pp. 1633-1647
Open Access | Times Cited: 21
Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review
Liang‐Fang Wang, Pingrun Chen, Si-Ke He, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 29, pp. 4481-4498
Open Access | Times Cited: 9
Sarcopenia assessed by computed tomography or magnetic resonance imaging is associated with the loss of response to biologic therapies in adult patients with Crohn's disease
Jingjing Liu, Hongye Tang, Tingting Lin, et al.
Clinical and Translational Science (2023) Vol. 16, Iss. 11, pp. 2209-2221
Open Access | Times Cited: 8
Long‐term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH‐LT study
Anthony Buisson, Maria Nachury, M Bazoge, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 59, Iss. 4, pp. 526-534
Closed Access | Times Cited: 8
Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease
Remi Mahmoud, Edo Savelkoul, Wout Mares, et al.
Clinical Gastroenterology and Hepatology (2022) Vol. 21, Iss. 3, pp. 750-760.e4
Open Access | Times Cited: 12
Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure
June Hwa Bae, Jung-Bin Park, Ji Eun Baek, et al.
Gut and Liver (2024) Vol. 18, Iss. 4, pp. 667-676
Open Access | Times Cited: 2
Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations
Ole Haagen Nielsen, Alexander Hammerhøj, Mark Ainsworth, et al.
Drugs (2024)
Closed Access | Times Cited: 2
Long-term effectiveness and safety of anti-TNF in pediatric-onset inflammatory bowel diseases: A population-based study
Mathurin Fuméry, Claire Dupont, Delphine Ley, et al.
Digestive and Liver Disease (2023) Vol. 56, Iss. 1, pp. 21-28
Closed Access | Times Cited: 5
Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-naïve and bio-experienced Crohn’s disease patients: a retrospective multicenter study
Ji Eun Na, Yong Eun Park, Jongha Park, et al.
BMC Gastroenterology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?
Suzanne I. Anjie, Melanie S. Hulshoff, Geert R. D’Haens
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 4, pp. 341-351
Closed Access | Times Cited: 4
Complementary Therapeutic Effect of Fecal Microbiota Transplantation in Ulcerative Colitis after the Response to Anti-Tumor Necrosis Factor Alpha Agent Was Lost: A Case Report
Jongbeom Shin, Ga Hyeon Baek, Boram Cha, et al.
Biomedicines (2024) Vol. 12, Iss. 4, pp. 800-800
Open Access | Times Cited: 1
Long-term effectiveness and safety of ustekinumab in Crohn’s disease: a prospective cohort study
Pepijn W. A. Thomas, Mark van Caem, Rachel West, et al.
European Journal of Gastroenterology & Hepatology (2022) Vol. 35, Iss. 3, pp. 261-269
Open Access | Times Cited: 7
Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies
Konstantinos Papamichael, Adam S. Cheifetz
Expert Opinion on Drug Metabolism & Toxicology (2021) Vol. 17, Iss. 12, pp. 1423-1431
Closed Access | Times Cited: 7
Letter: immunogenicity is not the root cause for loss of response to anti‐TNF agents in patients with IBD in TDM era
Dahham Alsoud, Bram Verstockt, Séverine Vermeire
Alimentary Pharmacology & Therapeutics (2022) Vol. 55, Iss. 7, pp. 885-886
Closed Access | Times Cited: 4
Persistence of subcutaneous versus intravenous infliximab in a real-life cohort: A propensity-score matched comparative analysis
L Bothorel, David Laharie, F. Poullenot, et al.
Digestive and Liver Disease (2024)
Closed Access
Page 1 - Next Page

Scroll to top